| abstract |
FIELD: medicine; pharmaceuticals.SUBSTANCE: group of inventions relates to a combination vaccine/inhibitor comprising an anticancer RNA vaccine which contains at least one RNA comprising at least one open reading frame (ORF), which encodes at least one tumor antigen, and a composition comprising at least one PD-1 pathway inhibitor, wherein the PD-1 pathway inhibitor is an anti-PD-1 or PD-L1 antagonist antibody. Also disclosed is the use of a PD-1 pathway inhibitor in combination with an RNA vaccine in a pharmaceutical composition, a kit and a method for treating oncological disease.EFFECT: simultaneous application of a combination of RNA vaccine / antagonist anti-PD-1 antibody leads to significant inhibition of tumor growth and is characterized by synergetic action.15 cl, 3 dwg, 1 tbl, 2 ex |